How Integrity Due Diligence In Lifesciences Is Changing Post COVID-19
Supply Chain Risk Management Now C-Suite Discussion
Senior Kroll executive outlines sharp shifts in scope of integrity and reputational due diligence in the healthcare and life sciences sector post COVID-19, with investors now seeking "very micro" insights of target firms.
